Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 16/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.69 |
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.69 |
| ▸ | KDR | P35968 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220795 | 0.99 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17520331 | 0.90 | EGFR (0.84) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13883015 | 0.89 | EGFR (0.84) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18979076 | 0.89 | EGFR (0.84) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25707230 | 0.88 | RET (0.68) | EGFRERBB2KDR | |
| SCHEMBL14066712 | 0.87 | HDAC3 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19220791 | 0.85 | EGFR (0.77) | EGFRKDR | |
| SCHEMBL8211781 | 0.84 | HDAC3 (0.83) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19006946 | 0.84 | EGFR (0.81) | EGFRERBB2KDR | |
| SCHEMBL16760603 | 0.84 | RET (0.82) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HDAC3 1036/4885HDAC4 933/4885HDAC1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.